ATAI
Atai Beckley·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ATAI
Atai Beckley N.V.
A clinical-stage biopharmaceutical company that developing treatment for mental health disorders
Prof. J.H. Bavincklaan 7, 1183 AT Amstelveen, The Netherlands
--
Atai Beckley N.V. was registered under the laws of the Netherlands on September 10, 2020. On January 11, 2021, it was renamed ATAI Life Sciences B.V. On November 5, 2025, it was renamed Atai Beckley N.V. Atai Beckley N.V. is a clinical-stage biopharmaceutical company dedicated to developing highly effective mental health therapies to improve patient outcomes. The company is advancing the development of a range of product candidates designed to address the complexity of mental health disorders.
Company Financials
EPS
ATAI has released its 2025 Q3 earnings. EPS was reported at -0.28, versus the expected -0.12, missing expectations. The chart below visualizes how ATAI has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ATAI has released its 2025 Q3 earnings report, with revenue of 749.00K, reflecting a YoY change of 1772.50%, and net profit of -61.10M, showing a YoY change of -132.21%. The Sankey diagram below clearly presents ATAI's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
